CGL Spectrum Community Pharmacy Commissioned Services
Here are the current CGL claim forms
Supervised Consumption Service
The supervised consumption programme in Hertfordshire is commissioned by CGL Spectum.
The 2017 Service Level Agreement (SLA) for community pharmacists providing supervised consumption of medication can be accessed here.
Needle Exchange Service
The needle exhange service provided by community pharmacy is commissioned by CGL Spectrum.
The 2017 Service Level Agreement (SLA) for community pharmacists providing needle exchange incorporating take home Naloxone can be accessed here.
Pharmacy CPD Training Events
CGL Spectrum regularly run pharmacy CPD training events for pharmacists already commissioned to provide drug and alcohol services by CRi Spectrum and for those pharmacists new to providing drug and alcohol services by CGL Spectrum. – 2019 dates – tbc
2019 – CGL Spectrum updates
17.03.2019 – Are launching their new All Ages Drug and Alcohol Service, on 01 April 2019.
They will now be delivering support for both adults and under-18s and have created a dedicated microsite detailing some of the changes and improvements they are making as part of the relaunch: https://www.changegrowlive.org/spectrum-drug-alcohol-recovery-service-hertfordshire
Here you can find sections aimed at specific teams and stakeholders, which they will be updating monthly, and bulletins you can read and share with your colleagues and service users. Pharmacy bulletin Issue 1
You can contact the implementation team by email via: Hertsstaff.firstname.lastname@example.org
Alternatively, you can still reachthem via the countywide email Herts@cgl.org.uk
Any questions they receive will be added to the next batch of updates so please don’t hesitate to contact them at any stage during this process.
28.02.2019 – Prescription change from generic buprenorphine to Espranor® (buprenorphine oral lyophilisate) 2mg and 8mg. Further details here
13.02.2019 – Espranor (buprenorphine oral lyophilisate) 2mg and 8mg – The matter was reported to them at a medical review two weeks after the service user was commenced on this medication. During the investigation the pharmacist confirmed this to have taken place. It is understood that the service user continued to receive generic buprenorphine instead of Espranor for a period of twelve days.
Cgl Spectrum would like to remind all pharmacists that Espranor is not interchangeable with generic buprenorphine sublingual tablets at the same dose (a “like for like” switch) as there are bioavailability differences between the formulations. There is also a difference in the way Espranor is administered, with the Espranor oral lyophilisate being placed directly on the tongue, rather than under the tongue.
As you have already been informed, Cgl are reviewing service users taking buprenorphine and where appropriate changing them over to Espranor. Prescribers will use their professional judgement regarding a suitable dose when making the transition. We will always prescribe Espranor by brand to reduce the chance of dispensing errors and to ensure our service users consistently receive the same brand of medication.
More information about Espranor can be obtained from www.medicines.org.uk where the Summary of Product Characteristics and Patient Information Leaflet can be found. Cgl Spectrum are happy to support pharmacists with any queries they may have regarding the use of Espranor or any other medication by our service users.
And finally, if you have not already done so, please inform us if you have been involved in any incidents involving Espranor / Buprenorphine in the usual way by reporting directly to us and in your normal CD reporting processes. The full letter is here.
08.01.2019 – Spectrum CGL have provided the most recent issue of the sharing good practice newsletter between CGL Spectrum & Local Pharmacists in Hertfordshire. It is the third edition of the Toolkit designed to share good practice and lessons learned from medication incidents involving their clients. Please contact email@example.com with any comments or questions relating to the content in this newsletter.
2018 – CGL Spectrum updates
CGL Spectrum has published their quarterly newsletter for December 2018.
11.12.2018 – CGL Spectrum have provided an updated bulletin with FAQ’s included around the changes from buprenorphine tablets to Espranor.
03.12.2018 – In view of recent buprenorphine supply and price fluctuations it has been decided to review service users that are prescribed buprenorphine tablets and, where appropriate, change them to Espranor. This is the most practical approach to ensure stability of treatment for service users and to minimise inconvenience to pharmacies. Read CGL’s newsletter with stock information and notification letter here.
There is currently a shortage of generic buprenorphine 2mgs tablets. Please see the letter from Dr Prun Bijral, Medical Director for Change Grow Live (cgl). Any questions or concerns please direct to Anna Marie Felice, Nurse Clinical Lead for cgl Spectrum in Hertfordshire on Mobile 07881 335 210. Any concerns regarding patient care should be directed to the specific HUB in the first instance. For this purpose please call our Single Point of Contact 0800 652 3169
CGL (previously CRI) Spectrum are commissioned to provide drugs and alcohol services within Hertfordshire by Hertfordshire County Council and they subcontract supervised consumption and needle exchange services from some community pharmacies.
Spectrum quarterly briefing July 2017
Please note that CGL Spectrum wrote to all pharmacies in May 2016 to make you aware of their intention to switch methadone solution 1mg/ml to Physeptone® oral solution 1mg/ml and Physeptone® oral solution sugar free 1mg/ml expected to take place during the week commencing Monday August 1st 2016. CGL outline that this is in line with the national guidance and will contribute towards making significant savings to prescribing costs, allowing for greater investment in other treatments and services locally. CGL will also be informing patients in writing of the switch but it would be beneficial for community pharmacies to support the informing of patients.